Resoundant
Private Company
Total funding raised: $2M
Overview
Resoundant commercializes Magnetic Resonance Elastography (MRE), a proprietary MRI-based technology that noninvasively measures tissue stiffness to diagnose and stage liver fibrosis. The company's FDA-cleared solution is positioned as a superior alternative to invasive liver biopsies and other elastography techniques like FibroScan. With its technology now integrated into thousands of global imaging sites and recently accepted into the FDA's Biomarker Qualification Program, Resoundant is expanding its role in both clinical diagnostics and pharmaceutical clinical trials for liver diseases like MASH.
Technology Platform
Magnetic Resonance Elastography (MRE): An MRI-based upgrade that uses low-frequency mechanical waves to create quantitative maps of tissue stiffness (elastograms) as a biomarker for disease.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Resoundant's primary competitors are noninvasive liver stiffness measurement devices like FibroScan (transient elastography) and various shear wave ultrasound elastography systems from companies such as SuperSonic Imagine and Siemens. These are generally lower-cost, more portable, and operated by hepatologists/gastroenterologists. MRE competes on superior accuracy, whole-liver assessment, and utility in obese patients, but at a higher cost and with limited access to MRI scanners.